REESE DAVID M 4
4 · AMGEN INC · Filed May 8, 2025
Insider Transaction Report
Form 4
AMGEN INCAMGN
REESE DAVID M
EVP & Chief Technology Officer
Transactions
- Award
Common Stock
2025-05-06+3,549→ 42,116 total - Award
Nqso (Right to Buy)
2025-05-06$270.44/sh+22,944$6,204,975→ 22,944 totalExercise: $270.44From: 2026-05-06Exp: 2035-05-06→ Common Stock (22,944 underlying)
Footnotes (3)
- [F1]The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/6/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- [F2]These shares include 397 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- [F3]These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/6/2026.